Can I get a GLP-1 if my BMI is under 27?

Below the BMI-27 line you’re outside FDA labeling, which makes everything that follows off-label — legal for a clinician to prescribe, but appropriately held to higher documentation standards. The scenarios that responsible programs recognize: BMI 25–27 with weight-related conditions. Some protocols extend eligibility here when comorbidities exist, on the logic that metabolic risk doesn’t begin at an arbitrary line. Reasonable, increasingly common, still off-label. The relapse-prevention case (lower BMIs). A person who weighed 240 lbs, lost 70 — by GLP-1, surgery, or grit — and is now fighting biology-driven regain presents a genuinely different clinical picture than someone who has never carried excess weight. Programs handling this lane properly require documented history (records, prior prescriptions, or photographic evidence of prior obesity), a written rationale (regain risk, metabolic adaptation), and typically restrict treatment to sub-therapeutic microdose protocols with mandatory synchronous provider review — not standard escalation ladders. Where every legitimate door closes: - BMI < 18.5 — absolute floor; continuing therapy below it is a discontinuation criterion, not a gray area. - Active eating-disorder symptoms — appetite suppressants and EDs are a dangerous combination; intake screens exist exactly for this. - Pure cosmetic goals at healthy weight (“the last 10 vanity pounds,” pre-event slimming, “wellness optimization”) — a program willing to prescribe here will cut corners elsewhere too. More on this. Practical takeaway: if you’re sub-27 with a real history, expect — and want — a program that asks for documentation and puts a human clinician in the loop. The ones that don’t ask are the ones to avoid.